Current Report Filing (8-k)
November 06 2020 - 12:00PM
Edgar (US Regulatory)
0000727207
false
0000727207
2019-08-06
2019-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported) August 6, 2020
Accelerate Diagnostics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction
of incorporation)
001-31822
|
|
84-1072256
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
3950 South Country Club Road, Suite 470, Tucson, Arizona
|
|
85714
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(520) 365-3100
(Registrant’s
telephone number, including area code)
Not Applicable
(Former name or former
address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
AXDX
|
The Nasdaq Stock Market LLC
(The Nasdaq Capital Market)
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On August 6, 2020, Accelerate Diagnostics,
Inc. (the “Company”) issued a press release announcing its financial results for the quarter ending June 30, 2020 and
hosted a conference call to discuss such results. A copy of the press release is attached hereto as Exhibit 99.1 and a copy of
the transcript of the conference call is attached hereto as Exhibit 99.2, each of which is incorporated herein by reference in
its entirety.
In accordance with General Instruction B.2
for Form 8-K, the information in this Item 2.02, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
November 6, 2020
|
ACCELERATE
DIAGNOSTICS, INC.
(Registrant)
|
|
|
|
|
|
/s/ Steve Reichling
|
|
|
Steve Reichling
|
|
|
Chief Financial Officer
|
|
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Sep 2023 to Sep 2024